World Lung 2023 – Flaura2 leaves a gap open for J&J
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
Roche stakes its KRAS claim
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.
Another twist in the TIGIT saga
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
More doubts swirl around Lumakras
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
